ArticleThe journal of prevention of Alzheimer's disease2026

ATNIVS biomarker heterogeneity in real-world patients receiving lecanemab.

Masanori Kurihara et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.